基于超声的子宫内膜癌淋巴结转移术前风险预测模型开发
该研究在16个欧洲中心纳入1501例子宫内膜癌患者,开发了结合内膜活检、临床和超声变量的混合效应逻辑回归模型预测淋巴结转移。模型AUC为0.73,在5%和20%风险阈值下敏感度分别为98%和48%,特异度分别为11%和80%,性能优于单纯活检或活检联合超声的风险分类。
要点
- 模型纳入年龄、异常出血持续时间、内膜活检结果、超声肿瘤范围及大小等预测因子。
- 模型AUC 0.73,校准斜率1.06,校准截距0.06。
- 模型在任意风险阈值下临床效用均高于单纯活检或活检联合超声分类。
核心结论
- 基于内膜活检结果及临床和超声特征,可在术前可靠估计子宫内膜癌患者个体淋巴结转移风险。
- 该模型优于单纯内膜活检或活检联合超声的风险分类。
研究设计与样本
- 在16个欧洲中心前瞻性纳入1501例子宫内膜癌术前经阴道超声检查的女性,开发混合效应逻辑回归模型预测淋巴结转移。
- 缺失数据(包括缺失淋巴结状态)采用插补,采用留中心交叉验证评估判别力、校准和临床效用。
主要发现
- 691例接受了淋巴结切除术,其中127例有淋巴结转移。
- 模型AUC为0.73(95%CI 0.68-0.78),校准斜率1.06(95%CI 0.79-1.34),校准截距0.06(95%CI -0.15至0.27)。
- 风险阈值5% vs 20%时,模型敏感度98% vs 48%,特异度11% vs 80%。
- 模型敏感度和特异度高于单纯内膜活检高风险分类(50% vs 35%和80% vs 77%)。
- 模型敏感度和特异度高于活检联合超声高风险分类(80% vs 75%和53% vs 52%)。
关键数值与推荐
- 模型预测因子包括年龄、异常出血持续时间、内膜活检结果、超声肿瘤范围、超声肿瘤大小及不可测量内膜的未定义肿瘤。
- 单纯内膜活检高风险定义为子宫内膜样癌G3/非子宫内膜样癌。
- 活检联合超声高风险定义为子宫内膜样癌G3/非子宫内膜样癌/深肌层浸润/宫颈间质浸润/宫外扩散。
临床怎么用
- 该模型可用于术前个体化评估子宫内膜癌患者淋巴结转移风险。
- 模型在任意给定风险阈值下临床效用均高于单纯内膜活检或活检联合超声分类。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop a preoperative risk model, using endometrial biopsy results and clinical and ultrasound variables, to predict the individual risk of lymph-node metastases in women with endometrial cancer. METHODS: A mixed-effects logistic regression model for prediction of lymph-node metastases was developed in 1501 prospectively included women with endometrial cancer undergoing transvaginal ultrasound examination before surgery, from 16 European centers. Missing data, including missing lymph-node status, were imputed. Discrimination, calibration and clinical utility of the model were evaluated using leave-center-out cross validation. The predictive performance of the model was compared with that of risk classification from endometrial biopsy alone (high-risk defined as endometrioid cancer Grade 3/non-endometrioid cancer) or combined endometrial biopsy and ultrasound (high-risk defined as endometrioid cancer Grade 3/non-endometrioid cancer/deep myometrial invasion/cervical stromal invasion/extrauterine spread). RESULTS: Lymphadenectomy was performed in 691 women, of whom 127 had lymph-node metastases. The model for prediction of lymph-node metastases included the predictors age, duration of abnormal bleeding, endometrial biopsy result, tumor extension and tumor size according to ultrasound and undefined tumor with an unmeasurable endometrium. The model's area under the curve was 0.73 (95% CI, 0.68-0.78), the calibration slope was 1.06 (95% CI, 0.79-1.34) and the calibration intercept was 0.06 (95% CI, -0.15 to 0.27). Using a risk threshold for lymph-node metastases of 5% compared with 20%, the model had, respectively, a sensitivity of 98% vs 48% and specificity of 11% vs 80%. The model had higher sensitivity and specificity than did classification as high-risk, according to endometrial biopsy alone (50% vs 35% and 80% vs 77%, respectively) or combined endometrial biopsy and ultrasound (80% vs 75% and 53% vs 52%, respectively). The model's clinical utility was higher than that of endometrial biopsy alone or combined endometrial biopsy and ultrasound at any given risk threshold. CONCLUSIONS: Based on endometrial biopsy results and clinical and ultrasound characteristics, the individual risk of lymph-node metastases in women with endometrial cancer can be estimated reliably before surgery. The model is superior to risk classification by endometrial biopsy alone or in combination with ultrasound. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Eriksson LSE, Epstein E, Testa AC, et al. Ultrasound-based risk model for preoperative prediction of lymph-node metastases in women with endometrial cancer: model-development study. Ultrasound Obstet Gynecol. 2020. PMID: 31840873. doi:10.1002/uog.21950
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。